Please assess the completion status of the following clinical trial:

Trial Title: 11C-acetate for Treatment Response After Radiotherapy for HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age~* Subject is willing to participate in the study and has signed the study informed consent~* Subject is available and willing to comply with the protocol evaluations~* Diagnosed hepatocellular carcinoma confined to a single lobe of the liver if undergoing 90Y radioembolization~* Diagnosed hepatocellular carcinoma confined to the liver if undergoing Stereotactic Body Radiation Therapy (SBRT)~* Under consideration for 90Y radioembolization or Stereotactic Body Radiation Therapy (SBRT)~Exclusion Criteria:~* Pregnant or planning to become pregnant within the next 12 months or breast-feeding~* GFR \< 45~* Life expectancy \< 6 months~* Claustrophobic and cannot tolerate imaging procedures~* Weigh \> 350 lb (upper weight limit of scanner beds)~* Special vulnerabilities (e.g. fetuses, neonatales, pregnant women, children, prisoners, institutionalized individuals).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy treatment monitoring of hepatocellular carcinoma (Type: OTHER): All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.

Based on this trial design, predict the completion outcome and termination type (if applicable).